Clinical implications of Brivaracetam Cross-Reactivity with levetiracetam immunoassay.

Published 10/22/2026

Research record: Clinical implications of Brivaracetam Cross-Reactivity with levetiracetam immunoassay.

Published in Epilepsy Behav; first publication date 2026-10-22. PMID 42913112.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Talk to a Specialist Browse all insights

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-10-22

Updated

2026-10-25

Disclaimer

professional use

References

Explore more

More from this section

A Validated Multi-Analyte Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Therapeutic Drug Monitoring and Targeted Toxicological Assessment of 54 Drugs and Metabolites in Human Serum.

More from this section

[Identification and interfering factors of falsely elevated androgen levels in clinical laboratory testing in women].

More from this section

Diagnostic accuracy of a multiplex nucleic acid amplification test for detecting gastrointestinal bacterial pathogens: A multicenter clinical study.